Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema. It also develops ARP-1536, a humanized monoclonal antibody that is in late stage preclinical development for the treatment of wet age-related macular degeneration; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a Phase 1a clinical trial for the treatment of inflammatory bowel disease.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone513-985-1920
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Aerpio Pharmaceuticals (OTCMKTS:ARPO) Frequently Asked Questions
What is Aerpio Pharmaceuticals' stock symbol?
Aerpio Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ARPO."
How were Aerpio Pharmaceuticals' earnings last quarter?
Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.04. View Aerpio Pharmaceuticals' Earnings History.
What price target have analysts set for ARPO?
4 brokers have issued 1-year price objectives for Aerpio Pharmaceuticals' shares. Their forecasts range from $1.00 to $8.00. On average, they expect Aerpio Pharmaceuticals' stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 874.0% from the stock's current price. View Analyst Price Targets for Aerpio Pharmaceuticals.
What is the consensus analysts' recommendation for Aerpio Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerpio Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aerpio Pharmaceuticals.
What are Wall Street analysts saying about Aerpio Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aerpio Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. It focuses on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The Company' product candidates include AKB?9778, ARP1536 and AKB-4924 which are in clinical stage. Aerpio Pharmaceuticals Inc. is based in Cincinnati, United States. " (10/9/2019)
- 2. HC Wainwright analysts commented, "Our price target is derived from an estimated market value of the firm at $43M, which includes a discounted cash flow- based asset value for AKB-9778 in glaucoma and AKB-4924 (GB004) in inflammatory bowel disease (IBS), using a 15% discount rate and 2% terminal growth rate, and probabilities of success at 20% and 10%,." (8/9/2019)
Has Aerpio Pharmaceuticals been receiving favorable news coverage?
News headlines about ARPO stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aerpio Pharmaceuticals earned a daily sentiment score of -1.5 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Aerpio Pharmaceuticals.
Who are some of Aerpio Pharmaceuticals' key competitors?
Some companies that are related to Aerpio Pharmaceuticals include Neoleukin Therapeutics (NLTX), Aduro BioTech (ADRO), Lipocine (LPCN), Mersana Therapeutics (MRSN), Aravive (ARAV), Checkpoint Therapeutics (CKPT), vTv Therapeutics (VTVT), Entasis Therapeutics (ETTX), Tiziana Life Sciences (TLSA), Humanigen (HGEN), Marinus Pharmaceuticals (MRNS), IMMUTEP LTD/S (IMMP), Neos Therapeutics (NEOS), Synlogic (SYBX) and Otonomy (OTIC).
What other stocks do shareholders of Aerpio Pharmaceuticals own?
Who are Aerpio Pharmaceuticals' key executives?
Aerpio Pharmaceuticals' management team includes the folowing people:
- Dr. Joseph H. Gardner, Founder, Pres & Director (Age 62)
- Mr. Kevin G. Peters M.D., Ph.D., Chief Scientific Officer & Sr. VP (Age 61)
- Dr. Stephen Pakola M.D., Chief Medical Officer (Age 49)
- Dr. Stephen J. Hoffman, CEO & Director (Age 64)
- Mr. Michael W. Rogers, Chief Financial Officer (Age 58)
How do I buy shares of Aerpio Pharmaceuticals?
Shares of ARPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Aerpio Pharmaceuticals' stock price today?
One share of ARPO stock can currently be purchased for approximately $0.46.
How big of a company is Aerpio Pharmaceuticals?
What is Aerpio Pharmaceuticals' official website?
How can I contact Aerpio Pharmaceuticals?
Aerpio Pharmaceuticals' mailing address is 9987 CARVER ROAD, CINCINNATI OH, 45242. The company can be reached via phone at 513-985-1920 or via email at [email protected]
MarketBeat Community Rating for Aerpio Pharmaceuticals (OTCMKTS ARPO)
MarketBeat's community ratings are surveys of what our community members think about Aerpio Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
